홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Cesium carbonate → 4-methyl-piperazine-1-carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide

HRID 2100413
인쇄

반응식

HRID 2100413 반응식
Br[C:2]1[CH:7]=[C:6]([CH2:8][NH:9][C:10]2[CH:28]=[CH:27][CH:26]=[CH:25][C:11]=2[C:12]([NH:14][C:15]2[CH:16]=[CH:17][C:18]3[C:22]([CH:23]=2)=[N:21][N:20]([CH3:24])[CH:19]=3)=[O:13])[CH:5]=[CH:4][N:3]=1.CC1(C)C2C(=C(P(C3C=CC=CC=3)C3C=CC=CC=3)C=CC=2)OC2C(P(C3C=CC=CC=3)C3C=CC=CC=3)=CC=CC1=2.C(=O)([O-])[O-].[Cs+].[Cs+].[CH3:77][N:78]1[CH2:83][CH2:82][N:81]([C:84]([NH2:86])=[O:85])[CH2:80][CH2:79]1>O1CCOCC1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd].CN(C=O)C>[CH3:24][N:20]1[CH:19]=[C:18]2[C:22]([CH:23]=[C:15]([NH:14][C:12]([C:11]3[CH:25]=[CH:26][CH:27]=[CH:28][C:10]=3[NH:9][CH2:8][C:6]3[CH:5]=[CH:4][N:3]=[C:2]([NH:86][C:84]([N:81]4[CH2:82][CH2:83][N:78]([CH3:77])[CH2:79][CH2:80]4)=[O:85])[CH:7]=3)=[O:13])[CH:16]=[CH:17]2)=[N:21]1
참가 물질반응 조건실험 절차후처리출처 및 근거반응 노트

참가 물질

8

반응물 4

HCID 10796Cesium carbonateHCID 4102614-Methylpiperazine-1-carboxamideHCID 6360441,1'-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(1,1-diphenylphosphine)HCID 231189722-[(2-bromo-pyridin-4-ylmethyl)-amino]-N-(2-methyl-2H-indazol-6-yl)-benzamide

생성물 1

HCID 115333714-methyl-piperazine-1-carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide
수율 22.5%

시약·촉매·용매 3

HCID 9811564Bis(dibenzylideneacetone)palladium촉매HCID 6228Dimethylformamide용매HCID 312751,4-Dioxane용매

반응 조건

온도
110 °C

실험 절차

2-[(2-bromo-pyridin-4-ylmethyl)-amino]-N-(2-methyl-2H-indazol-6-yl)-benzamide (110 mg, 0.25 mmol) was suspended in dioxane (3 mL) and treated consecutively with DMF (1 mL), Pd2dba3 (5 mg, 0.005 mmol), Xantphos (9 mg, 0.015 mmol), cesium carbonate (98 mg, 0.3 mmol) and 4-methyl-piperazine-1-carboxylic acid amide (184 mg, 1.3 mmol). The reaction mixture was placed under a nitrogen atmosphere and heated for 3 hours at 110° C. (bath temperature). On cooling the volatiles were removed in vacuo and the residue was partitioned between CH2Cl2 and water. The organic phase was washed with brine, dried, filtered and concentrated. The residue was purified by chromatography using Isolute® Flash NH2 (Separtis) as stationary phase (Gradient elution: 100% CH2Cl2 to CH2Cl2/EtOH 95:5) to give 4-methyl-piperazine-1-carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide (28 mg, 22%) as a foam; 1H-NMR (300 MHz, d6-DMSO) 10.14 (1H, s), 9.11 (1H, s), 8.25 (1H, S), 8.14 (1H, d), 8.10 (1H, s), 7.95 (1H, t), 7.80 (1H, s), 7.72 (1H, d), 7.63 (1H, d), 7.23-7.32 (2H, m), 6.94 (1H, d), 6.66 (1H, t), 6.53 (1H, d), 4.43 (2H, d), 4.13 (3H, s), 3.41-3.44 (4H, m), 2.25-2.28 (4H, m), 2.17 (3H, s); m/z (ES+) 499.

후처리

  1. temperatureOn cooling the volatiles
  2. customwere removed in vacuo
  3. customthe residue was partitioned between CH2Cl2 and water
  4. washThe organic phase was washed with brine
  5. customdried
  6. filtrationfiltered
  7. concentrationconcentrated
  8. customThe residue was purified by chromatography
  9. washas stationary phase (Gradient elution: 100% CH2Cl2 to CH2Cl2/EtOH 95:5)

출처 및 근거

ORD 기록
ord-09e260b53c2246e8a702493a489a471b
출처 데이터셋
uspto-grants-2009_08
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US07572794B2

반응 노트

이 페이지에서참가 물질반응 조건실험 절차후처리출처 및 근거반응 노트